CAU
BSX icon

Caxton Associates (UK)’s Boston Scientific BSX Stock Holding History

Caxton Associates (UK)’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,445
Closed -$342K – 769
2026
Q1 		$342K Sell
5,445
-11,307
-67% -$905K 0.01% 575
2025
Q4 		$1.6M Buy
16,752
+13,013
+348% +$1.28M 0.03% 255
2025
Q3 		$365K Sell
3,739
-721
-16% -$74.7K 0.01% 512
2025
Q2 		$479K Sell
4,460
-1,016
-19% -$103K 0.01% 438
2025
Q1 		$552K Buy
+5,476
New +$551K 0.02% 455

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Caxton Associates (UK)'s BSX Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 5,445 shares — an estimated $342K sold.

Caxton Associates (UK) first reported a position in BSX in Q1 2025 and held it in 5 quarters. The position peaked at $1.6M in Q4 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Caxton Associates (UK) reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 5,445 Boston Scientific shares in Q2 2026, an estimated $342K.
  • Caxton Associates (UK) first reported a position in Boston Scientific in Q1 2025 and held it in 5 quarters.
  • Caxton Associates (UK)'s Boston Scientific position peaked at $1.6M in Q4 2025.
  • 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.